Evidence map›Paper›PMID 40673002›Full record

ArticleJAC-antimicrobial resistance2024

Development of antibacterial drug + bacteriophage combination assays.

Marie Attwood, Pippa Griffins, Alan Noel, Theo Josephs, Karen Adler, Martha Clokie, Alasdair MacGowan

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Bacteriophage pharmacodynamics studied in anJAC-antimicrobial resistance · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marie AttwoodBristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, North Bristol NHS Trust, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.ORCID https://orcid.org/0000-0003-1047-2098
Pippa GriffinsBristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, North Bristol NHS Trust, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Alan NoelBristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, North Bristol NHS Trust, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Theo JosephsDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Karen AdlerDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Martha ClokieDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Alasdair MacGowanBristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, North Bristol NHS Trust, Pathology Quarter, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The best methods to study the interactions between phages and antibacterials are unclear. As laboratory methodologies used to assess conventional antibacterials are established, we assessed their ability to evaluate phage plus antibacterial. Methods: The efficacy of three characterized Results: The PmIC Conclusions: Microbroth methodologies based on ISO 2776-1:2019 lend themselves to be viable options for phage assessment, alone or in combination with antibiotics. The reproducibility of PmIC and familiarity of the methodology described allows for laboratory validation for phage and antibiotic combinations.

Identifiers

PMID40673002
PMCPMC11251025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.